Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunology

ATX restricts anti-tumor eosinophil responses

Nature Cancer volume 5, pages 221–223 (2024)Cite this article

Subjects

Autotaxin (ATX) produces lysophosphatidic acid (LPA), which directly promotes pancreatic ductal adenocarcinoma (PDAC) growth, but the role of the tumor microenvironment (TME) in ATX-driven tumor growth is unclear. ATX–LPA signaling in PDAC is now shown to shape the TME by inhibiting eosinophil recruitment, resulting in increased tumor growth.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ATX inhibition in PDAC unleashes CCL11-dependent anti-tumoral eosinophil recruitment.

References

  1. Hilmi, M. et al. Lancet Gastroenterol. Hepatol. 8, 1129–1142 (2023).

    Article  PubMed  Google Scholar 

  2. Bhattacharyya, S. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00703-y (2024).

    Article  PubMed  Google Scholar 

  3. Auciello, F. R. et al. Cancer Discov. 9, 617–627 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chae, C. S. et al. Cancer Discov. 12, 1904–1921 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Matas-Rico, E. et al. Cell Rep. 37, 110013 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Manohar, M., Verma, A.K., Venkateshaiah, S. U. & Mishra, A. J. Gastroenterol. Pancreatol. Liver Disord. 5 (2017).

  7. Grisaru-Tal, S. et al. Oncoimmunology 10, 1859732 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ohkuma, R. et al. Pancreas 50, 167–175 (2021).

    Article  CAS  PubMed  Google Scholar 

  9. Gurtner, A. et al. Nature 615, 151–157 (2023).

    Article  ADS  CAS  PubMed  Google Scholar 

  10. Mesnil, C. et al. J. Clin. Invest. 126, 3279–3295 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Grisaru-Tal, S. et al. Cancer Res. 81, 5555–5571 (2021).

    Article  CAS  PubMed  Google Scholar 

  12. Jacquelot, N. et al. Nat. Immunol. 22, 851–864 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Grisaru-Tal, S., Rothenberg, M. E. & Munitz, A. Nat. Immunol. 23, 1309–1316 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V. & Fendt, S. M. Dev. Cell 56, 1363–1393 (2021).

    Article  CAS  PubMed  Google Scholar 

  15. Deken, M. A. et al. Immunooncol. Technol. 18, 100384 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel

    Sharon Grisaru-Tal & Ariel Munitz

Authors
  1. Sharon Grisaru-Tal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ariel Munitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariel Munitz.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grisaru-Tal, S., Munitz, A. ATX restricts anti-tumor eosinophil responses. Nat Cancer 5, 221–223 (2024). https://doi.org/10.1038/s43018-023-00718-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00718-5

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer